Distalmotion has grabbed hold of a de novo clearance for its Dexter surgical robot, a system designed for hospitals as well as ambulatory surgery centers. The robotic assistant was cleared by the FDA ...
The MarketWatch News Department was not involved in the creation of this content. Lausanne, Switzerland, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Distalmotion, the global MedTech company empowering access to ...
Lausanne, Switzerland, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Distalmotion today announced continued momentum in its clinical trial plans to support indication expansion of its DEXTER® Robotic Surgery ...
Lausanne, Switzerland, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Distalmotion, the global MedTech company empowering access to the benefits of robotic surgery in outpatient sites of care, today announced that ...
Lausanne, Switzerland, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Distalmotion has been granted De Novo approval by the U.S. Food and Drug Administration (FDA) to market the Dexter Surgical Robot for adult ...
Lausanne, Switzerland, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Less than 30 days after receiving FDA De Novo marketing authorization, Distalmotion’s Dexter Surgical Robot has successfully treated the first ...
Lausanne, Switzerland, May 28, 2025 (GLOBE NEWSWIRE) -- Distalmotion, the global MedTech company empowering access to the benefits of robotic surgery in more sites of care, today announced that it has ...
Lausanne, Switzerland, June 24, 2025 (GLOBE NEWSWIRE) -- Distalmotion, a global MedTech company advancing access to robotic surgery, has reached a key milestone in its US expansion with the first ...